According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, ...

A large number of studies have focused on mental health declines associated with glaucoma. For example, about one-third of ...

The Center, which was launched in 2023, will now be named The Barry Family Center for Ophthalmic Artificial Intelligence and ...

Corneal cross-linking has led to a significant decline in corneal transplant rates for keratoconus globally. Cross-linking ...

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris ...

Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at ...

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from ...

AD is a neurodegenerative disease characterized by neuronal loss in the cerebral cortex and the formation of extracellular ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...